A Randomized, Double blind, Active controlled, Phase 2 Clinical Trial to Assess the Immunogenicity and Safety of GBP411 in Healthy Infants

Trial Profile

A Randomized, Double blind, Active controlled, Phase 2 Clinical Trial to Assess the Immunogenicity and Safety of GBP411 in Healthy Infants

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs GBP 411 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Sponsors SK Chemicals
  • Most Recent Events

    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top